Literature DB >> 16000453

Countrywide spread of community- and hospital-acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon.

Carole Moubareck1, Ziad Daoud, Noha I Hakimé, Monzer Hamzé, Nicole Mangeney, Hiam Matta, Jacques E Mokhbat, Raymond Rohban, Dolla Karam Sarkis, Florence Doucet-Populaire.   

Abstract

A prospective study was carried out to assess the extent of carriage of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae at both hospital and community levels in Lebanon. A total of 1,442 fecal samples were collected from hospital-based patients and 58 from health care workers of six Lebanese tertiary care general hospitals located in different areas of Lebanon between January and March 2003. A total of 382 fecal samples were also collected from healthy subjects between April and June 2003. The samples analysis led to the identification of 118 strains as ESBL producers based on the synergistic effects between clavulanate and selected beta-lactams (ceftazidime and cefotaxime). These strains were isolated from 72 subjects: 61 patients, 2 health care workers, and 9 healthy subjects. One representative strain per subject was selected, and a total of 72 nonduplicate ESBL producers, including a high majority of Escherichia coli (n = 56), Klebsiella pneumoniae (n = 9), Enterobacter cloacae (n = 6), and Citrobacter freundii (n = 1), were characterized. The molecular analysis revealed that the majority of the strains (83%) express CTX-M-15 ESBL (pI 8.6). SHV-5a ESBL (pI 8.2) was produced by 18% of the strains. DNA macrorestriction analysis of ESBL-producing E. coli presented 38 different genotypes, revealing the absence of clonal link among these strains. In addition to the fact that the present study highlights the emergence and the countrywide dissemination of CTX-M-15-producing E. coli in Lebanon, it represents the first report of an SHV-5a-producing C. freundii.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000453      PMCID: PMC1169093          DOI: 10.1128/JCM.43.7.3309-3313.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  Epidemiology of extended spectrum beta-lactamases.

Authors:  A Philippon; S Ben Redjeb; G Fournier; A Ben Hassen
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

2.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

3.  ["Beta-lactamase enzymogram": an agar adaptation of the iodometric method (author's transl)].

Authors:  R Labia; M Barthélémy
Journal:  Ann Microbiol (Paris)       Date:  1979-10

4.  Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases.

Authors:  G P Katsanis; J Spargo; M J Ferraro; L Sutton; G A Jacoby
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

5.  Characterization of an SHV-5 related extended broad-spectrum beta-lactamase in Enterobacteriaceae from Western Australia.

Authors:  L Mulgrave; P V Attwood
Journal:  Pathology       Date:  1993-01       Impact factor: 5.306

Review 6.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum beta-lactamases in York, UK.

Authors:  C J Munday; G M Whitehead; N J Todd; M Campbell; P M Hawkey
Journal:  J Antimicrob Chemother       Date:  2004-08-04       Impact factor: 5.790

8.  Characterization of extended-spectrum-beta-lactamase (CTX-M-15)-producing strains of Salmonella enterica isolated in France and Senegal.

Authors:  François-Xavier Weill; Jean-David Perrier-Gros-Claude; Marie Demartin; Sophie Coignard; Patrick A D Grimont
Journal:  FEMS Microbiol Lett       Date:  2004-09-15       Impact factor: 2.742

9.  Epidemiological study by pulsed-field gel electrophoresis of an outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a geriatric hospital.

Authors:  A Gouby; C Neuwirth; G Bourg; N Bouziges; M J Carles-Nurit; E Despaux; M Ramuz
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

10.  Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 beta-lactamase and which were isolated in 14 French hospitals.

Authors:  G Arlet; M Rouveau; I Casin; P J Bouvet; P H Lagrange; A Philippon
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

View more
  34 in total

1.  Prevalence and characterisation of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates in healthy volunteers in Tunisia.

Authors:  R Ben Sallem; K Ben Slama; V Estepa; A Jouini; H Gharsa; N Klibi; Y Sáenz; F Ruiz-Larrea; A Boudabous; C Torres
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-08       Impact factor: 3.267

2.  Dissemination in Portugal of CTX-M-15-, OXA-1-, and TEM-1-producing Enterobacteriaceae strains containing the aac(6')-Ib-cr gene, which encodes an aminoglycoside- and fluoroquinolone-modifying enzyme.

Authors:  Elisabete Machado; Teresa M Coque; Rafael Cantón; Fernando Baquero; João Carlos Sousa; Luísa Peixe
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  CTX-M-3 and CTX-M-15 extended-spectrum beta-lactamases in isolates of Escherichia coli from a hospital in Algiers, Algeria.

Authors:  Nadjia Ramdani-Bouguessa; Nuno Mendonça; Joana Leitão; Eugénia Ferreira; Mohamed Tazir; Manuela Caniça
Journal:  J Clin Microbiol       Date:  2006-09-20       Impact factor: 5.948

4.  CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors.

Authors:  Jean-Philippe Lavigne; Hélène Marchandin; Julien Delmas; Jérôme Moreau; Nicole Bouziges; Evelyne Lecaillon; Laurent Cavalie; Hélène Jean-Pierre; Richard Bonnet; Albert Sotto
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

5.  Carriage of CTX-M-15-producing Escherichia coli isolates among children living in a remote village in Senegal.

Authors:  Etienne Ruppé; Paul-Louis Woerther; Abdoulaye Diop; Anne-Marie Sene; Annaelle Da Costa; Guillaume Arlet; Antoine Andremont; Bernard Rouveix
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

6.  Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment.

Authors:  Sibhghatulla Shaikh; Jamale Fatima; Shazi Shakil; Syed Mohd Danish Rizvi; Mohammad Amjad Kamal
Journal:  Saudi J Biol Sci       Date:  2014-08-17       Impact factor: 4.219

7.  Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.

Authors:  Nuno Mendonça; Joana Leitão; Vera Manageiro; Eugénia Ferreira; Manuela Caniça
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

Review 8.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  High prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar.

Authors:  Todisoa Andriatahina; Frédérique Randrianirina; Eliosa Ratsima Hariniana; Antoine Talarmin; Honoré Raobijaona; Yves Buisson; Vincent Richard
Journal:  BMC Infect Dis       Date:  2010-07-12       Impact factor: 3.090

10.  Characterization of CTX-M ESBLs in Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae clinical isolates from Cairo, Egypt.

Authors:  Noha G Khalaf; Mona M Eletreby; Nancy D Hanson
Journal:  BMC Infect Dis       Date:  2009-06-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.